CD38 / CD19 / Firefly Luciferase CHO Recombinant Cell Line

Catalog #
78149
$10,340 *
Size: 2 vials
Qty
*US Pricing only. For international pricing, please contact your local distributor.
Purchase
Description

Recombinant clonal stable CHO cell line constitutively expressing full length human CD38 protein (also known as ADPRC1, Genbank accession #NM_001775) and human CD19 protein (also known as B4 or CVID3, Genbank accession #NM_001770). This cell line was derived from our CHO-K1 Luciferase cells (BPS Bioscience, #79725), therefore it also constitutively expresses the firefly luciferase reporter. Surface expression of CD38 and CD19 were confirmed by flow cytometry.

Purchase of this cell line is for research purposes only; commercial use requires a separate license. View the full terms and conditions.

Synonyms
cluster of differentiation 38 cells, ADP-Ribosyl Cyclase 1 cell line, NAD(+) Nucleosidase cell line, ADPRC 1 cell line, TNFRSF17 cells, Cluster of Differentiation 19 cell lines, B-lymphocyte surface antigen B4 cells
Product Info
Storage and Usage
Citations
Host Cell Line
CHO K1 cell line, Chinese Hamster Ovary, epithelial-like cells, adherent
Species
Human
Supplied As
2 vials of frozen cells. 2 x 106 cells in 1 ml of 10% DMSO
Materials Required But Not Supplied

Materials Required for Cell Culture

Name  Ordering Information
Thaw Medium 3 BPS Bioscience #60186
Growth Medium 3K BPS Bioscience #78041

 

Materials Required for Cellular Assay

Name Ordering Information
ONE-Step™ Luciferase Assay System BPS Bioscience #60690
96-well tissue culture-treated white clear-bottom assay plate  
Luminometer  
UniProt #
P28907, P15391
Mycoplasma Testing

The cell line has been screened using the MycoAlert™ Mycoplasma Detection kit (Lonza, #LT07-218) to confirm the absence of Mycoplasma species.

Background

The CD38 protein is a dimeric, non-lineage-restricted, type II transmembrane glycoprotein that synthesizes and hydrolyzes the second messengers cyclic ADP-ribose and NADP. CD38 is highly expressed by lymphoid and myeloid cells, particularly plasma cells. Increased CD38 expression on chronic lymphocytic leukemia (CLL) cells is linked to aggressive disease features and poor clinical outcome. CD38 is used as a prognostic marker for patients with CLL and multiple myeloma (MM), and is an ideal target for immunotherapy in CLL and MM.


B-lymphocyte antigen CD19 (Cluster of Differentiation 19), also known as B-Lymphocyte Surface Antigen B4 and CVID3, is a transmembrane protein expressed in follicular dendritic cells and all B lineage cells except plasma cells. CD19 plays two major roles in human B cells. It acts as an adaptor protein to recruit cytoplasmic signaling proteins to the membrane and it works within the CD19/CD21 complex to decrease the threshold for B cell receptor signaling pathways. Due to its presence on all B cells, it is a biomarker for B lymphocyte development and lymphoma diagnosis and can be used as a target for leukemia immunotherapies. CD19-targeted therapies based on T cells that express CD19-specific chimeric antigen receptors (CARs) have been utilized for their antitumor abilities in patients with CD19+ lymphoma and leukemia, such as Non-Hodgkin’s Lymphoma (NHL), CLL and ALL.